Frank Douglas K
Department of Otolaryngology-Head and Neck Surgery, Institute for Head and Neck Cancer, Beth Israel Medical Center, Phillips Ambulatory Care Center, Albert Einstein College of Medicine, New York, NY, USA.
Surg Oncol Clin N Am. 2002 Jul;11(3):589-606, vi-vii. doi: 10.1016/s1055-3207(02)00021-2.
Head and neck cancer, because of its anatomic accessibility and poor overall survival rate, has become a frequent target of novel gene therapy intervention strategies. Viral and nonviral vectors have been used to transfer a variety of tumor suppressor genes, suicide genes, and immunologic genes into head and neck cancer cells in both the laboratory and clinical setting. Gene therapy as an isolated treatment modality will probably not replace standard treatment modalities in the management of head and neck cancer. It seems likely, however, that gene transfer will find its way into the multidisciplinary care of the head and neck cancer patient, where novel treatments are combined with standard therapies in order to maximize tumor response.
头颈癌由于其解剖位置易于接近且总体生存率较低,已成为新型基因治疗干预策略的常见靶点。在实验室和临床环境中,病毒载体和非病毒载体都已被用于将多种肿瘤抑制基因、自杀基因和免疫基因导入头颈癌细胞。作为一种单独的治疗方式,基因治疗可能不会取代头颈癌治疗中的标准治疗方式。然而,基因转移似乎有望融入头颈癌患者的多学科治疗中,即在这种治疗中,新的治疗方法与标准疗法相结合,以最大限度地提高肿瘤反应。